Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Ironwood buys VectivBio for $1 billion

by Shi En Kim
May 25, 2023 | A version of this story appeared in Volume 101, Issue 17

 

Ironwood Pharmaceuticals, a health-care firm focused on gastrointestinal disorders, will acquire VectivBio in a $1 billion all-cash deal. VectivBio specializes in developing treatments for rare conditions such as short bowel syndrome with intestinal failure and acute graft-versus-host disease. The Swiss company’s lead asset is a glucagon-like peptide-2 analog; it is in Phase 3 clinical trials and has an expected readout by year-end.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.